Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer
- 1 June 2014
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 24 (5) , 857-864
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical OutcomesJNCI: Journal of the National Cancer Institute, 2009
- Evaluation of the Symptom Representation Questionnaire (SRQ) for Assessing Cancer-Related SymptomsJournal of Pain and Symptom Management, 2008
- Ovarian cancer: a focus on management of recurrent diseaseNature Clinical Practice Oncology, 2006
- Assessing health-related quality of life in palliative care: Comparing patient and physician assessmentsEuropean Journal of Cancer, 2006
- External validity of randomised controlled trials: “To whom do the results of this trial apply?”The Lancet, 2005
- Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials GroupEuropean Journal of Cancer, 2005
- Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancerGynecologic Oncology, 2004
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- Abbreviated instrument to measure hope: development and psychometric evaluationJournal of Advanced Nursing, 1992
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983